Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zota Health CareNSE:ZOTA -0.64%79 PB Ratio is 6.31 as of Jul. 29, 2026, which is 15% below its 10-year median of 7.42. GuruFocus rates NSE:ZOTA with a GF Score™ of 79/100 and a GF Value™ of ₹1,649.42 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Zota Health Care ranks worse than 76.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-29), Zota Health Care's share price is ₹1274.90. Zota Health Care's Book Value per Share for the quarter that ended in Mar. 2026 was ₹202.15. Hence, Zota Health Care's PB Ratio of today is 6.31.
The historical rank and industry rank for Zota Health Care's PB Ratio or its related term are showing as below:
NSE:ZOTA'
s PB Ratio Range Over the Past 10 Years
Min: 3.82 Med: 7.42 Max: 17.79
Current: 6.31
During the past 13 years, Zota Health Care's highest PB Ratio was 17.79. The lowest was 3.82. And the median was 7.42.
NSE:ZOTA's PB Ratio is ranked worse than 76.94% of 1227
companies
in the Biotechnology industry
Industry Median: 2.75
vs NSE:ZOTA: 6.31
During the past 12 months, Zota Health Care's average Book Value Per Share Growth Rate was 169.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 87.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 43.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 24.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zota Health Care was 87.50% per year. The lowest was -1.70% per year. And the median was 19.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zota Health Care PB Ratio Related Terms
Zota Health Care PB Ratio Historical Data
* Premium members only.
The historical data trend for Zota Health Care's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zota Health Care's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zota Health Care PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zota Health Care's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zota Health Care's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zota Health Care (NSE:ZOTA) has a PB Ratio of 6.31 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zota Health Care and its competitors. This is 15% below median its historical median of 7.42. Over the past decade, Zota Health Care's PB Ratio has ranged from 3.82 to 17.79. According to the industry distribution chart, Zota Health Care ranks #944 out of 1227 companies in the Biotechnology industry, placing it in the top 76.9%.
Is Zota Health Care's PB Ratio too high?
Zota Health Care's current PB Ratio of 6.31 is 15% below median its 10-year median of 7.42. Over the past 10 years, this metric has ranged from a low of 3.82 to a high of 17.79. The Biotechnology industry median PB Ratio is 2.75. Zota Health Care's value of 6.31 is 129.5% above this industry median. Based on the distribution chart, Zota Health Care ranks #944 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zota Health Care has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zota Health Care's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zota Health Care ranks #944 out of 1227 companies for PB Ratio. This places Zota Health Care in the lower half of its industry. The industry median PB Ratio is 2.75. Zota Health Care's value of 6.31 is 129.5% above this benchmark. Historically, Zota Health Care's own PB Ratio has ranged from 3.82 to 17.79 over the past decade. While the company's 10-year median is 7.42 vs. the industry median of 2.75, Zota Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zota Health Care's current PB Ratio of 6.31 is 129.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zota Health Care and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zota Health Care's current PB Ratio is 6.31, which is 15% below median its own 10-year median of 7.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zota Health Care stock overvalued right now?
Based on GuruFocus' analysis, Zota Health Care (NSE:ZOTA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,649.42, compared to a current price of ₹1,274.90 — trading 22.7% below its estimated fair value. The current PB Ratio is 6.31, which is 15% below median its 10-year median of 7.42 and 129.5% above the Biotechnology industry median of 2.75. Zota Health Care's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zota Health Care (NSE:ZOTA), the current PB Ratio is 6.31 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zota Health Care (NSE:ZOTA) Overvalued in 2026?
Based on GuruFocus' analysis, Zota Health Care stock appears to be undervalued.
The current stock price of ₹1,274.90 is trading 22.7% below its estimated GF Value™ of ₹1,649.42.
GuruFocus considers Zota Health Care to be Modestly Undervalued.
Key valuation signals for NSE:ZOTA:
PB Ratio: 6.31 (15% below median its 10-year median of 7.42)
GF Value™: ₹1,649.42 vs. price of ₹1,274.90 (22.7% below fair value)
Industry Position: 129.5% above the Biotechnology median (#944 of 1227)
No single metric tells the full story. See the NSE:ZOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zota Health Care Ltd is engaged in the manufacturing, trading, and export of pharmaceutical products. The company caters to both domestic and international markets. It offers a vast range of pharmaceutical, nutraceutical, ayurvedic, and OTC products in India and overseas as well.
79GF Score
Get the complete analysis for NSE:ZOTA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZOTA has been successfully added to your 
